# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elvis Presley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML003-SYN-TD
- Date: 1974-07-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Coleman Ashby-Nakagawa, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- He is tired all the time, sleepy in the afternoon and cannot keep up the energy his shows need **S**
- He has put on weight and feels bloated and constipated, and is self-conscious about it on stage **S**
- He wants to stop needing so many pills without going through withdrawal or missing a show **S**

## Your goals

- Stop full-agonist opioids and stabilize on buprenorphine without significant withdrawal. Target: 1974-08-07. Recorded outcome: Buprenorphine 16 mg a day since the consultation; no withdrawal after the first day; cravings low. **S**
- One prescriber and one pharmacy for all controlled medicines. Target: 1974-09-23. Recorded outcome: Monitoring program shows only this clinic's prescriptions since intake. **S**
- Lower the diazepam dose slowly, 5 to 10% every two to four weeks, toward stopping. Target: 1974-10-28. Recorded outcome: 40 mg a day after the alprazolam was combined into it, to 30 mg at four months; no withdrawal symptoms; taper continuing. **S**
- Home blood pressure below 130/80. Target: 1974-08-07. Recorded outcome: Home average 146/94 to 126/80 on amlodipine and valsartan. **S**
- Lose 5% or more of body weight. Target: 1974-10-28. Recorded outcome: 109.0 to 102.6 kg (5.9%) on tirzepatide, with more activity and earlier meals. **S**
- CPAP on at least 70% of nights for four hours or more, with less daytime sleepiness. Target: 1974-10-28. Recorded outcome: CPAP on 88% of nights; Epworth 14 to 6. **S**
- A bowel movement at least every two days without straining. Target: 1974-08-07. Recorded outcome: Every one to two days on buprenorphine and polyethylene glycol. **S**

## What we agreed to do

- Safe prescribing of controlled drugs: a brown-bag reconciliation of every medicine, a prescription drug monitoring program check before every controlled prescription, a written single-prescriber agreement with one pharmacy, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused tablets; no controlled drug stopped abruptly. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Addiction medicine consultation to make the substance use diagnoses, start medication for opioid use disorder, and plan the benzodiazepine change and taper. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**
- Overdose prevention: naloxone nasal spray at home and in the tour bag, two people around him taught to use it, no alcohol or other sedatives, and the danger of opioids with benzodiazepines and with the sleep apnea that is suspected explained. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020) **S**
- Safety: a structured safety assessment, a written safety plan, firearms locked and unloaded with ammunition separate, the 988 Suicide & Crisis Lifeline, and safety review at every visit; PHQ-9 and GAD-7 at each review. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026) **S**
- Buprenorphine for opioid use disorder: buprenorphine with naloxone started in the office at a COWS score above 8, 16 mg a day, weekly contact for the first month, prescriptions from this clinic only, counseling, and no tapering off while he is doing well; buprenorphine is not withheld because he takes a benzodiazepine. Guideline: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020) **S**
- Benzodiazepine change and taper: alprazolam combined into diazepam (40 mg a day), held steady until buprenorphine is stable, then reduced by about 5 to 10% every two to four weeks, paused during engagements, illness or withdrawal symptoms, never stopped abruptly; CBT for anxiety and insomnia alongside; no Z-drug or other sedative in its place. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**
- Hypertension: home readings confirmed stage 2 hypertension, so two first-line drugs were started in one pill (amlodipine with valsartan), with potassium and creatinine two to four weeks later, a target below 130/80, sodium reduction, activity and weight loss. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026) **S**
- Obstructive sleep apnea: CPAP from the split-night titration, with adherence data reviewed at each visit and a travel machine for tours; no sedative added at night. Guideline: Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline (2017); Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019) **S**
- Weight treated without stigma: earlier meals, protein and fiber, more walking and karate between tours, and tirzepatide once weekly, chosen because it also treats obstructive sleep apnea with obesity, raised slowly with a watch on nausea and constipation. Guideline: AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity (2022); Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (2024) **S**
- Constipation on opioids: polyethylene glycol daily with senna as needed, fluids and fiber; a peripherally acting opioid antagonist only if these fail; an abdominal radiograph only for pain, distension or vomiting. Guideline: American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation (2019); American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation (2023) **S**
- Glaucoma: latanoprost continued, his ophthalmologist kept informed of every new medicine, no phentermine, decongestant or anticholinergic sleep aid, steroids only when essential and with his ophthalmologist's knowledge, and urgent care for eye pain with halos. Guideline: Primary Open-Angle Glaucoma Preferred Practice Pattern (2020); CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026) **S**
- Performing and touring: no medication change in the week before an engagement, weekly video visits while away, controlled prescriptions sent only to one named pharmacy, a written plan for missed doses, naloxone and any prescribed devices in the tour bag, and a letter he controls for venues. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**

## Follow-up

- 1974-07-10: Establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referral **S**
- 1974-07-17: One-week review, seen the same day by addiction medicine: diagnoses, buprenorphine started in the office, the benzodiazepines combined into one, the sleep study and home blood pressure results **S**
- 1974-08-07: Three-week review on buprenorphine: withdrawal and cravings, the first benzodiazepine taper step, blood pressure treatment, CPAP, constipation and weight, and planning for a Las Vegas engagement **S**
- 1974-08-14: Periodic adult preventive visit **S**
- 1974-09-23: Ten-week review after the Las Vegas engagement and a back strain: buprenorphine, the taper, weight treatment, sleep apnea and planning for a three-week tour **S**
- 1974-10-28: Four-month review after the tour: recovery, the taper, blood pressure, weight, liver tests, sleep and the plan ahead **S**

This teaching document does not replace care from a qualified clinician.
